ESALF - Eisai refocuses R&D efforts as cancer research unit shutters
- Eisai ( OTCPK:ESALY ) is reorganizing its R&D efforts under the idea of "Deep Human Biology Learning" that will focus on the root cause of diseases and utilize artificial intelligence.
- The launch of the reorganization is slated for Oct. 1.
- As part of the rejiggering, the Japanese pharma is also closing its oncology therapies development wing, H3 Biomedicine, FierceBiotech reported.
- Begun in 2010, the H3 shutdown will result in 88 layoffs.
- Under the new R&D structure, Eisai ( OTCPK:ESALF ) said conditions will be viewed under a disease continuum, and will support drug development through AI, genomic analysis, biomarkers and patient imaging.
- The company added that research on Alzheimer's disease and related brain diseases will fall under the new Alzheimer's Disease and Brain Health division.
- Eisai's lead asset, lecanemab for Alzheimer's, recently received priority review from the U.S. FDA .
For further details see:
Eisai refocuses R&D efforts as cancer research unit shutters